Business highlights in Q3 2024
- In July the company announced the publication of the international patent application regarding pudafensine’s dosage regime for the treatment of erectile dysfunction
Business highlights after this reporting period
- Nothing to report.
Financial Highlights
| Third Quarter (2024-07-01 – 2024-09-30) |
| Net revenue were TDKK 0 (0) |
| Operating loss, EBIT was TDKK -3,233 (-5,191) |
| Earnings per share before and after dilution was DKK –0.06 (-0.09) |
| Cash: TDKK 11,979 (21,781) |
| Solidity: 92% (36%) |
| First Nine Months (2024-01-01 – 2024-09-30) |
| Net revenues were TDKK 0 (0) |
| Operating loss, EBIT was TDKK -11,801 (-22,750) |
| Earnings per share before and after dilution was DKK –0.22 (-0.46) |
Solidity: equity divided by assets.
The Board of Directors have decided that interim reports will be published in English only.
Link to the full report
https://www.initiatorpharma.com/en/investors/reports-and-presentations/